Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G, Nakaigawa N, Umemoto S, Kobayashi K, Shibata Y, Tsutsumi S, Yasui M, Ohtake S, Suzuki T, Osaka K, Muraoka K, Hasumi H, Kondo K, Igarashi Y, Sasada T, Kishida T, Yao M. Noguchi G, et al. Among authors: sasada t. Cancer Chemother Pharmacol. 2020 Jul;86(1):75-85. doi: 10.1007/s00280-020-04088-y. Epub 2020 Jun 14. Cancer Chemother Pharmacol. 2020. PMID: 32537714
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H. Azuma K, et al. Among authors: sasada t. Cancer Chemother Pharmacol. 2009 Aug;64(3):565-73. doi: 10.1007/s00280-008-0907-3. Epub 2009 Jan 3. Cancer Chemother Pharmacol. 2009. PMID: 19123003
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T. Matsuo N, et al. Among authors: sasada t. Int J Cancer. 2019 Mar 1;144(5):1170-1179. doi: 10.1002/ijc.31923. Epub 2018 Nov 12. Int J Cancer. 2019. PMID: 30307035
Prospects for a personalized peptide vaccine against lung cancer.
Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T. Nakahara Y, et al. Among authors: sasada t. Expert Rev Vaccines. 2019 Jul;18(7):703-709. doi: 10.1080/14760584.2019.1635461. Epub 2019 Jun 28. Expert Rev Vaccines. 2019. PMID: 31225971 Free article. Review.
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Jikuya R, Kishida T, Sakaguchi M, Yokose T, Yasui M, Hashizume A, Tatenuma T, Mizuno N, Muraoka K, Umemoto S, Kawai M, Yoshihara M, Nakamura Y, Miyagi Y, Sasada T. Jikuya R, et al. Among authors: sasada t. Cancer Immunol Immunother. 2020 Oct;69(10):2041-2051. doi: 10.1007/s00262-020-02608-6. Epub 2020 May 18. Cancer Immunol Immunother. 2020. PMID: 32424467 Free PMC article.
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
Nakahara Y, Matsutani T, Igarashi Y, Matsuo N, Himuro H, Saito H, Yamada K, Murotani K, Hoshino T, Azuma K, Sasada T. Nakahara Y, et al. Among authors: sasada t. Cancer Immunol Immunother. 2021 Oct;70(10):2881-2892. doi: 10.1007/s00262-021-02900-z. Epub 2021 Mar 9. Cancer Immunol Immunother. 2021. PMID: 33751180 Free PMC article.
221 results